The FDA approved oral semaglutide to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D).
Mallory Telese, PharmD, BA, BCACP, CSP
Advertisement
Articles by Mallory Telese, PharmD, BA, BCACP, CSP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Notifies Flu Vaccine Makers to Add Warning for Increased Febrile Seizure Risk in Young Children Day Following Vaccination
2
AI-Powered Digital Twins Offer a New Window Into Tumor Metabolism in Brain Cancer
3
In 2026, Pharmacists Will Be Driving Change Across the Care Continuum
4
FDA Finds No Increased Suicide Risk With GLP-1 Medications, Requests Removal of Warning Labels
5